login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
DESIGN THERAPEUTICS INC (DSGN) Stock News
USA
- NASDAQ:DSGN -
US25056L1035
-
Common Stock
6.49
USD
-0.19 (-2.84%)
Last: 10/29/2025, 8:24:35 PM
6.49
USD
0 (0%)
After Hours:
10/29/2025, 8:24:35 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
DSGN Latest News, Press Relases and Analysis
All
Press Releases
2 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Appoints Justin Gover to Board of Directors
2 months ago - By: Design Therapeutics, Inc.
- Mentions:
CMPS
XENE
Design Therapeutics Appoints Justin Gover to Board of Directors
2 months ago - By: Benzinga
- Mentions:
IVVD
Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller
2 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
2 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
3 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
3 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
5 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
5 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
5 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
6 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
6 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
6 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
6 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
6 months ago - By: Yahoo Finance
- Mentions:
LRCX
IBM
MA
ABBV
...
Lam Research Corporation (LRCX): Jim Cramer Is Blunt — “Lam Is a Gem”
6 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
6 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
6 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
7 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
7 months ago - By: Bright Peak Therapeutics, Inc.
- Mentions:
ANAB
XERS
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
7 months ago - By: Benzinga
- Mentions:
IRIX
LXRX
PTIX
DBVT
...
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
8 months ago - By: Design Therapeutics, Inc.
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
8 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
8 months ago - By: Design Therapeutics, Inc.
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
Please enable JavaScript to continue using this application.